Bremer Bank National Association Increases Holdings in Novo Nordisk A/S (NYSE:NVO)

Bremer Bank National Association grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 1.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 49,479 shares of the company’s stock after acquiring an additional 924 shares during the period. Bremer Bank National Association’s holdings in Novo Nordisk A/S were worth $4,256,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the second quarter valued at about $25,000. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S in the third quarter worth about $28,000. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S in the third quarter worth about $42,000. Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the third quarter worth about $48,000. Finally, M&R Capital Management Inc. grew its stake in Novo Nordisk A/S by 260.5% in the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock worth $49,000 after purchasing an additional 297 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of research reports. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Performance

NVO opened at $78.74 on Monday. The business’s 50 day moving average is $97.76 and its 200-day moving average is $117.05. The stock has a market cap of $353.33 billion, a PE ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.